Beximco Pharmaceuticals Limited — Results for the year ended 30 June 2026

Beximco Pharma posts strong growth in revenue, profit, and cash for FY2026.

What the company is saying

Beximco Pharmaceuticals Limited is highlighting a year of robust financial and operational performance for the period ended 30 June 2026. The company reports net revenue of BDT 56,265.9m, up 14.5% year-on-year, with domestic sales growing 15.1% to BDT 51,852.5m and export sales up 8.3% to BDT 4,413.4m. Profit after tax surged 30.9% to BDT 9,160.8m, and earnings per share increased to BDT 20.17 from BDT 15.56. The board is recommending a 60% cash dividend, equivalent to BDT 6.00 per share, framing this as a direct result of strong performance. Cash and cash equivalents rose sharply to BDT 6,668.0m from BDT 1,700.1m, and operating cash flow reached BDT 9,514.8m. Operational achievements include the launch of Triko (generic Trikafta), Eletriptan in the US, and Sotalol in Canada, along with multiple international product registrations. The announcement positions these launches and registrations as key drivers of revenue momentum.

What the data suggests

The disclosed figures show clear acceleration in both top-line and bottom-line performance. Net revenue increased 14.5% to BDT 56,265.9m, with domestic sales outpacing exports at 15.1% growth versus 8.3%. Profit after tax rose 30.9% to BDT 9,160.8m, indicating margin expansion. EPS climbed to BDT 20.17 from BDT 15.56, reflecting improved profitability per share. Cash and cash equivalents nearly quadrupled to BDT 6,668.0m, and operating cash flow was strong at BDT 9,514.8m, supporting liquidity and dividend capacity. The 60% cash dividend (BDT 6.00/share) is well-covered by these results. Operationally, the company delivered on product launches in key international markets—Triko, Eletriptan (US), and Sotalol (Canada)—and completed multiple international registrations, substantiating the claim of revenue momentum. The data is comprehensive, with all key metrics and YoY comparisons disclosed, and no material gaps between claims and evidence.

Analysis

The announcement is grounded in realised, audited financial and operational results for the year ended 30 June 2026. All major claims—revenue, profit after tax, EPS, cash, and operating cash flow—are supported by specific, year-on-year comparative figures. Operational achievements, such as product launches in the US and Canada and completed international registrations, are described as completed events, not future aspirations. The only forward-looking statement is the board's recommended dividend, which is a standard next-step following strong results and does not constitute promotional hype. There is no evidence of exaggerated language or narrative inflation; the tone is proportionate to the disclosed performance. No large capital outlay or long-dated, uncertain returns are referenced.

Risk flags

• ●Sustaining high growth rates in both domestic and export markets may become challenging as the base increases, especially given the lower export growth rate (8.3%) compared to domestic (15.1%). Any slowdown could impact future profitability and dividend capacity.
• ●The company's expansion into international markets through new product launches and registrations exposes it to regulatory, competitive, and reimbursement risks in jurisdictions like the US and Canada. Delays or setbacks in these markets could affect future revenue streams.
• ●A significant increase in cash and cash equivalents to BDT 6,668.0m strengthens liquidity, but efficient capital allocation will be necessary to maintain returns and avoid underutilised cash drag.

Bottom line

Beximco Pharmaceuticals Limited delivered strong financial results for FY2026, with double-digit growth in revenue, profit, and cash. The 60% cash dividend is well-supported by robust operating cash flow and a sharp increase in cash reserves. Operational execution—evidenced by product launches in the US and Canada and multiple international registrations—has translated into tangible financial gains. The narrative is credible, with every major claim substantiated by detailed figures and clear YoY comparisons. Investors should focus on the company's ability to sustain this growth, particularly in exports and new international markets, and on management's capital allocation decisions given the increased cash position. The most important takeaway is that Beximco Pharma is currently delivering on both financial and operational fronts, providing a solid foundation for continued shareholder returns.

Announcement summary

(LSE:BXP) Beximco Pharmaceuticals Limited reported net revenue of BDT 56,265.9m for the year ended 30 June 2026, representing a 14.5% year-on-year increase. Domestic sales grew by 15.1% to BDT 51,852.5m, while export sales increased by 8.3% to BDT 4,413.4m. Profit after tax rose 30.9% to BDT 9,160.8m (£56.6m). Earnings per share increased to BDT 20.17, compared to BDT 15.56 in the previous year (2024-25). The board has recommended a 60% cash dividend, equivalent to BDT 6.00 per share. Cash and cash equivalents at year-end strengthened to BDT 6,668.0m, up from BDT 1,700.1m in the prior period. Operating cash flow for the year was BDT 9,514.8m. During the year, Beximco Pharma launched Triko (a generic version of Trikafta), Eletriptan in the US, and Sotalol in Canada. The company also completed multiple international product registrations, which supported revenue momentum. The board's dividend recommendation reflects the company's strong financial performance. The launch of new products and successful international registrations contributed to the company's growth. The increase in cash and cash equivalents demonstrates improved liquidity. The rise in operating cash flow indicates strong underlying business operations. The company continues to expand its international presence through new product launches and registrations.

Disagree with this article?